Influenza Pipeline Drugs & Treatment Landscape (2023) | Companies - Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, and others

DelveInsight's, "Influenza Pipeline Insight 2023" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the Influenza pipeline drug profiles, including Influenza clinical trials and nonclinical stage products. It also covers the Influenza therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Influenza Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Influenza clinical trials studies, Influenza NDA approvals (if any), and product development activities comprising the technology, Influenza collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Influenza Pipeline treatment landscape of the report, click here @ Influenza Pipeline Outlook- https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Influenza Pipeline Report
• Over 120+ Influenza companies are evaluating 120+ Influenza pipeline therapies in various stages of development, and their anticipated acceptance in the Influenza market would significantly increase market revenue.
• The leading Influenza Companies includes Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others
• Promising Influenza Pipeline Therapies includes mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, DAS181, ALVR106, OVX836, VIR-2482, POLB 001, CD388, CT-P27, KD-404, AVA2300, CVSQIV, GSK3206641A, UniFlu, CC-42344, AV5080, mRNA-1073, UFluA, PF-07852352, GP681, ZSP1273, Sing2016, BW-1014, AVM0703, DAS181, HNC042, HEC116094, Adjuvanted Cell Culture Influenza Vaccine (aQIVc), NanoFlu, MT-8972, MT-7529, MT-2654, PrEP-001,GSK4382276A, mRNA Influenza Vaccine, LUNAR-FLU, M-001, Adintrevimab, PDS0202, Neumifil, Influenza vaccine, ETH47, GC3114A, and others.
• mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Currently, it is in Phase III stage of clinical trial evaluation to treat patients suffering from Seasonal Influenza.
• SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company's proprietary technology, the DiversitAb™ platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune compromised.
• Codagenix has utilized a design platform to construct a live-attenuated, universal flu vaccine, CodaVax™-H1N1. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is being evaluated in Phase I stage of clinical trial evaluation to treat Influenza virus infections.

Influenza Overview
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death.

For further information, refer to the detailed Influenza Unmet Needs, Influenza Market Drivers, and Influenza Market Barriers, click here for Influenza Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Influenza Emerging Drugs Profile
• mRNA-1010: Moderna
• SAB-176: SAB Biotherapeutics
• INNA-051: ENA Respiratory Pty Ltd
• CODA-VAX H1N1: Codagenix
• ALVR106: AlloVir

Influenza Pipeline Therapeutics Assessment
There are approx. 120+ Influenza companies which are developing therapies for Influenza. The Influenza companies which have their Influenza drug candidates in the most advanced stage, i.e. phase III include, Moderna.

Request a sample and discover the recent advances in Influenza Ongoing Clinical Trial Analysis and Medications, click here @ Influenza Treatment Landscape- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Influenza Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Influenza Therapeutics Market include-
Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others

Dive deep into rich insights for drugs for Influenza Pipeline, click here @ Influenza Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Influenza Pipeline Report
• Coverage- Global
• Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others
• Influenza Pipeline Therapies- mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, DAS181, ALVR106, OVX836, VIR-2482, POLB 001, CD388, CT-P27, KD-404, AVA2300, CVSQIV, GSK3206641A, UniFlu, CC-42344, AV5080, mRNA-1073, UFluA, PF-07852352, GP681, ZSP1273, Sing2016, BW-1014, AVM0703, DAS181, HNC042, HEC116094, Adjuvanted Cell Culture Influenza Vaccine (aQIVc), NanoFlu, MT-8972, MT-7529, MT-2654, PrEP-001,GSK4382276A, mRNA Influenza Vaccine, LUNAR-FLU, M-001, Adintrevimab, PDS0202, Neumifil, Influenza vaccine, ETH47, GC3114A, and others.
• Influenza Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Got Queries? Find out the related information on Influenza Merger and acquisitions, Influenza Licensing Activities @ Influenza Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Influenza: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Influenza - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. mRNA-1010: Moderna
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. INNA-051: ENA Respiratory Pty Ltd
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CODA-VAX H1N1: Codagenix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Influenza Key Companies
21. Influenza Key Products
22. Influenza- Unmet Needs
23. Influenza- Market Drivers and Barriers
24. Influenza- Future Perspectives and Conclusion
25. Influenza Analyst Views
26. Influenza Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit

This release was published on openPR.